DOMESTIC AND FOREIGN EXPERIENCE ANALYSIS OF PLANNING AND REGULATORY RESEARCH IN PHARMACEUTICALS
https://doi.org/10.25207/1608-6228-2017-24-3-149-159
Abstract
Aim. To conduct an analysis of the management of innovation activities for innovative medicines market launch in Russia and abroad.
Material and Methods. The methods of cognition (including methods of empirical (observation, comparison) and theoretical research (analysis, synthesis, aggregation)), expert assessments, SWOT analysis were used in the research.
Results. The analysis of domestic and foreign experience in planning and regulating research in the field of pharmaceutics is carried out. Despite the fact that at present a powerful ramified state apparatus for regulating scientific research and development in the field of medicine has been formed in the Russian Federation, the pharmaceutical science remains divided. This leads to a decrease in the effectiveness of research in the field of pharmaceuticals. At the same time, in developed countries, interdepartmental coordination and advisory bodies (councils, commissions) are active, often at the highest level. This testifies to the high attention given in these countries to interdepartmental interaction and intersectoral projects in the field of research and development.
Conclusion. Foreign R & D support systems are characterized by a number of differences from domestic mechanisms. A number of recommendations based on the experience of foreign colleagues for future measures to modernize existing and introduce new mechanisms for state support of research in the field of pharmaceuticals in Russia are proposed.
About the Author
A. A. SEMIN
Federal State Budgetary Educational Institution of Higher Education «St. Petersburg State Chemical Pharmaceutical Academy» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
197376, Russian Federation, St. Petersburg, Professora Popova st., 14, Lit. A; tel.: +7 (916) 909-21-82
References
1. Lin A.A., Goncharov V., Ivichev E.A. The field of pharmaceuticals is the most high-technology part of world economy // SEI GESUND. 2016. – №1. – P. 23-25.
2. The transcript of the Meeting of the Government Import Substitution Commission on 8 July 2016 "O realizacii proektov importozamescheniya v farmacevticheskoj i medicinskoj promyshlennosti" ("On the import substitution projects in the pharmaceutical and medical industry"). Available at: http://government.ru/news/23699/ (accessed 1 December 2016).
3. Narkevich I.A., Semin A.A., Lin A.A. and etc. Market launch of innovative drugs in Russia: Problems and solutions. Pharmacy. 2017; Т.66. №2. 3-6. (In Russ., English abstract)].
4. Presidential Address to the Federal Assembly of the Russian Federation 2017. Available at: http://www.kremlin.ru/events/president/news/53379/ (accessed 1 December 2016).
5. Order of the Russian Ministry of Health No. 66 of February 13, 2013 (as amended on 07/04/2016) "On the Approval of the Strategy of Medicinal Supply to the Population of the Russian Federation for the Period until 2025 and the Plan for its Implementation".
6. Order of the Ministry of Industry and Trade of the Russian Federation of October 23, 2009 No. 965 "On the approval of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period to 2020".
7. Decree of the Government of the Russian Federation No. 294 of April 15, 2014 (as amended on May 7, 2017) "On approval of the state program of the Russian Federation" Health Development"
8. Decree of the Government of the Russian Federation No. 305 of April 15, 2014 (as amended on March 31, 2017) "On approval of the state program of the Russian Federation" Development of the pharmaceutical and medical industry "for 2013-2020."
9. Decree of the Government of the Russian Federation No. 301 of April 15, 2014 (revised as of 30.03.2017) "On approval of the state program of the Russian Federation" Development of science and technology "for 2013-2020".
10. Zavarukhin V.P., Korchmar L.L., Rubvalter D.A., Rudensky O.V. The functional structure of research and innovation systems in OECD countries. Information- analytical bulletin CSRS. 2006; № 4. 1-107. (In Russ., English abstract).
11. Doroshenko G.S. The financing of scientific research and innovation: dis. … cand. econ. sciences. Krasnodar. Kuban State University; 2003. 184 p. (In Russ.).
12. Rubvalter D.A., Shuvalov S.S. Experience of leading foreign countries in the field of state regulation of the sphere of research and development. Information- analytical bulletin CSRS. 2007; № 1: 1-78. (In Russ.).
13. Public / Private Partnerships for Innovation: Policy Rationale, Trends and Issues. OECD. 2004; p.8.
14. Summary on international background of innovative development. The Russian Ministry of Economic Development. 2011.
15. Available at: http://economy.gov.ru/minec/about/structure/depsvod/doc20110407_02/ (accessed 5 June 2017).
16. Caloghirou N., Vonortas N., Loannides S. Science and Technology Policies Towards Research Joint Ventures. Science and Public Policy. 2002; Т. 29. №2.
17. Dezhina I.G. State regulation of science in Russia: dis. … dr. econ. sciences. M. The Institute of world economy and international relations of the RAS; 2007. 421 p. (In Russ.).
18. National Science Board. 2006. Science and Engineering Indicators 2006. Arlington, VA: National Science Foundation. 2006; Т. 1.
19. SBIR/STTR. Frequently Asked Questions – General Questions. SBIR/STTR America's Seed Fund. 2015. Available at: http://www.sbir.gov (accessed 27 December 2016).
20. Horizon's 2020 SME Instrument. European Commission. Executive Agency for SMEs. 2015. Available at: http://ec.europa.eu (accessed 6 June 2017).
21. SM SMEs – European Commission. Related Horizon 2020 sections. European Commission. 2015. Available at: https://ec.europa.eu (accessed 6 June 2017).
22. Fast Track to Innovation pilot (2015-2016). European Commission. 2015. Available at: http://ec.europa.eu. (accessed 27 December 2016).
23. Ivanov V.V., Ivanova N.I., Rosenbum J., Heisbers H. National innovation systems of Russia and the EU. M. Center for Studies in the Problems of the Development of Science RAS. 2006. 280 p. (In Russ.).
24. Access to Finance – EUROPA. Your Europe. 2015. August. Available at: http://europa.eu. (accessed 6 March 2017).
Review
For citations:
SEMIN A.A. DOMESTIC AND FOREIGN EXPERIENCE ANALYSIS OF PLANNING AND REGULATORY RESEARCH IN PHARMACEUTICALS. Kuban Scientific Medical Bulletin. 2017;(3):149-159. (In Russ.) https://doi.org/10.25207/1608-6228-2017-24-3-149-159
Views:
377
Email this article 